[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of Air Force Medicial University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":140},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,71,92,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640050","phase-1-fecal-microbiota-transplantation-for-elderly-patients-with-hfpef-a-randomized-controlled-trial-100640050",false,"NCT07628777","Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial","Fecal Microbiota Transplantation for Elderly Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 1.Aged ≥ 60 years old;\n* 2.Meeting the diagnostic criteria for HFpEF:\n\n  1. Consistent with the epidemiological and demographic characteristics of HFpEF patients;\n  2. Presence of clinical symptoms and\u002For signs of heart failure;\n  3. Cardiac imaging examination indicating LVEF ≥ 50%;\n  4. In sinus rhythm: BNP ≥ 35 pg\u002Fml and\u002For NT-proBNP ≥ 125 pg\u002Fml;In atrial fibrillation: BNP ≥ 105 pg\u002Fml and\u002For NT-proBNP ≥ 365 pg\u002Fml;\n  5. Meet at least one of the following conditions:\n\n     1. LVMI ≥ 115 g\u002Fm² (male) or ≥ 95 g\u002Fm² (female);\n     2. LAVI \\> 34 ml\u002Fm²;\n     3. Relative wall thickness \\> 0.42, or left ventricular free wall thickness \\> 12 mm;\n     4. Septal e' \\\u003C 7 cm\u002Fs, or lateral e' \\\u003C 10 cm\u002Fs, or average E\u002Fe' ≥ 14;\n     5. Tricuspid regurgitation velocity \\> 2.8 m\u002Fs, or pulmonary artery systolic pressure \\> 35 mmHg;\n* 3.NYHA functional class Ⅱ-Ⅲ;\n* 4.Complicated with metabolic diseases such as hypertension, diabetes and obesity;\n* 5.Accompanied by gastrointestinal symptoms;\n* 6.Well-tolerated to current anti-heart failure regimens with stable medication for at least 1 month;\n* 7.Stable heart failure condition without acute exacerbation;\n* 8.Basically normal cognitive function, capable of understanding scale assessment contents;\n* 9.Able to perform daily activities independently;\n* 10.Fully understanding the purpose of this clinical trial, voluntary participation and signing of written informed consent.\n\nExclusion Criteria:\n\n* 1.Symptoms caused by non-cardiac diseases;\n* 2.Patients with any contraindication to Fecal Microbiota Transplantation (FMT):\n\n  1. Patients with severe intestinal barrier damage induced by various causes, such as sepsis, active massive gastrointestinal bleeding, intestinal perforation;\n  2. Patients diagnosed with fulminant colitis or toxic megacolon;\n  3. Patients unable to tolerate enteral nutrition meeting 50% of calorie requirements due to severe diarrhea, significant fibrous intestinal stenosis, severe gastrointestinal hemorrhage, high-output intestinal fistula and other conditions;\n  4. Patients with congenital or acquired immunodeficiency diseases;\n  5. Patients receiving high-risk immunosuppressive or cytotoxic drugs recently, such as rituximab, doxorubicin, or moderate-to-high dose steroids (prednisone ≥ 20 mg\u002Fd) administered continuously for more than 4 weeks;\n  6. Severely immunosuppressed patients with neutrophil count \\\u003C 1500\u002Fmm³;\n* 3.History of myocardial infarction, coronary artery bypass grafting, or any event that may reduce LVEF within 6 months before enrollment (unless LVEF ≥ 50% was confirmed);\n* 4.Received valve replacement surgery within 6 months before enrollment;\n* 5.Poorly controlled blood pressure (SBP ≥ 180 mmHg or DBP ≥ 100 mmHg);\n* 6.Current acute decompensated heart failure requiring intervention;\n* 7.Resting heart rate \\> 120 beats per minute, or complicated with malignant arrhythmia;\n* 8.Significant coronary artery disease requiring PCI revascularization;\n* 9.Severe renal insufficiency (serum creatinine \\> 442 μmol\u002FL) or patients on dialysis;\n* 10.Pre-existing gastrointestinal diseases, including ulcerative colitis, Crohn's disease, irritable bowel syndrome, chronic diarrhea;\n* 11.Current malignant tumors requiring anti-tumor treatment;\n* 12.Complicated with acute diseases or acute exacerbation of chronic diseases at present;\n* 13.Participation in other interventional clinical trials or oral intake of probiotic preparations within the past 3 months.","ALL","60 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a single-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in elderly patients with heart failure with preserved ejection fraction (HFpEF).\n\nHFpEF is a common type of heart failure in older adults, often associated with poor quality of life and frequent hospitalizations. Recent research suggests that changes in gut bacteria may contribute to the progression of HFpEF. FMT aims to restore a healthy gut microbiome, which may improve heart function and reduce symptoms.\n\nParticipants will be randomly assigned to receive either FMT or a placebo treatment. The primary goal is to compare changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score between the two groups at 20 weeks. Secondary goals include assessing improvements in exercise capacity (6-minute walk test), NYHA functional class, and safety outcomes.\n\nThe study will enroll 50 elderly patients (aged ≥60 years) with confirmed HFpEF. All participants will receive standard medical care for HFpEF throughout the study. This trial is sponsored by The First Affiliated Hospital of Air Force Medical University and conducted in accordance with ethical standards.",[27,28],"Heart Failure With Preserved Ejection Fraction (HFPEF)","Chronic Heart Failure",[30,31,32,33],"Heart Failure with Preserved Ejection Fraction","HFpEF","Fecal Microbiota Transplantation","FMT","NOT_YET_RECRUITING","2026-06-01",{"date":37,"type":38},"2026-06-05","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2028-12-31",{"name":44,"class":45},"The First Affiliated Hospital of Air Force Medicial University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100633726","analysis-of-influencing-factors-for-the-development-of-ptsd-in-emergency-department-trauma-patients-100633726","NCT07530432","Analysis of Influencing Factors for the Development of PTSD in Emergency Department Trauma Patients","Inclusion Criteria:\n\n* Age between 18 and 65 years old (inclusive);\n* Experienced a life-threatening major traumatic event, clearly diagnosed by a clinician;\n* The patient is able to communicate normally with medical staff through language;\n* The subject is fully informed and voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\n* History of psychiatric disorders or current use of psychotropic medications;\n* Pre-existing cognitive impairment (e.g., dementia, Alzheimer's disease);\n* Terminal illnesses (such as advanced malignant tumors, end-stage organ failure, advanced neurological diseases, or any other condition judged by the attending physician to have a life expectancy of less than 6 months);\n* Inability to cooperate with follow-up.","18 Years","65 Years",{"count":56,"type":20},250,"6 Months","OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of key factors such as cognitive flexibility, social support, and physiological stress on the occurrence of Post-Traumatic Stress Disorder (PTSD) in adult trauma patients treated in the emergency department. The main question it aims to answer is:\n\nAmong emergency department patients who have experienced major trauma, can factors such as early post-trauma cognitive flexibility, level of social support, inflammatory markers, and trauma severity predict the development of PTSD within 6 months? Participants will complete a series of online questionnaires and clinical assessments at baseline, 1 month, 3 months, and 6 months after the traumatic event.",[61,62],"Trauma Patients","PTSD","2026-04-08",{"date":65,"type":38},"2026-04-15",{"date":67,"type":20},"2026-03-20",{"date":69,"type":20},"2026-12",{"name":44,"class":45},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":46},"100613407","phase-1-safety-and-efficacy-of-cd19-chimeric-antigen-receptor-t-cell-car-t-in-the-treatment-of-refractory-membranous-nephropathy-100613407","NCT07266181","Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy","Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in the Treatment of Refractory Membranous Nephropathy","Inclusion Criteria:\n\n* Confirmed as primary membranous nephropathy (PMN) by renal biopsy.\n* Classified as moderate-risk or high-risk refractory membranous nephropathy (rMN).\n* Moderate-risk rMN is defined as: eGFR ≥ 90 ml\u002Fmin\u002F1.73m² AND 24-hour urinary protein \\> 3.5g\u002Fd, with a reduction of no more than 50% within 6 months of receiving renin-angiotensin system inhibitor (RASi) therapy.\n* High-risk rMN is defined as meeting one of the following:\n\n  1. eGFR \\\u003C 60 ml\u002Fmin\u002F1.73m² and\u002For persistent proteinuria \\> 8g\u002Fd for more than 6 months.\n  2. Normal eGFR with proteinuria \\> 3.5g\u002Fd and ≤50% reduction after 6 months of RASi therapy, PLUS at least one of the following: Serum albumin \\\u003C 25g\u002FL; PLA2R antibody \\> 50 RU\u002FmL; Urinary α1-microglobulin \\> 40 μg\u002Fmin; Urinary IgG \\> 1 μg\u002Fmin; Urinary β2-microglobulin \\> 250 mg\u002Fd; IgG\u002Falbumin clearance ratio \\> 0.20.\n* Diagnosis of rMN requires failure of adequate first-line immunosuppressive therapy (≥6 months of steroids+cyclophosphamide, CNI, or rituximab), defined by any of the following: persistent high-titer anti-PLA2R antibody; for antibody-negative patients, persistent nephrotic syndrome (protein \\>3.5g\u002Fd, albumin \\\u003C30g\u002FL); \\\u003C50% reduction in proteinuria.\n* Age ≥ 18 years.\n* Adequate organ function, defined as:\n\n  1. Renal: eGFR ≥ 30 ml\u002Fmin\u002F1.73m².\n  2. Hepatic: ALT and AST ≤ 2.5 x ULN; Total bilirubin ≤ 1.5 x ULN.\n  3. Cardiac: LVEF ≥ 50%; NYHA Class I or II; No significant arrhythmias requiring intervention; No major cardiovascular events within the past 6 months.\n  4. Respiratory: SpO2 \\> 92% on room air.\n* Ability to understand and willingness to sign an Informed Consent Form.\n\nExclusion Criteria:\n\n* Secondary membranous nephropathy (e.g., due to SLE, malignancy, drugs, infection).\n* Active infection requiring IV antibiotics, active tuberculosis, or positive viral serology indicating active infection, including:\n\n  1. HBV: HBsAg (+) and\u002For HBcAb (+) with detectable HBV DNA.\n  2. HCV: HCV Ab (+) with detectable HCV RNA.\n  3. HIV Ab (+).\n  4. Active EBV or CMV infection (IgM+ or DNA above normal).\n  5. Positive syphilis (Treponema pallidum) antibody (requires evaluation for active infection).\n* Severe uncontrolled comorbidities, including:\n\n  1. Uncontrolled hypertension (persistent SBP \\> 160 mmHg or DBP \\> 100 mmHg).\n  2. Uncontrolled diabetes (HbA1c \\> 8% or random glucose ≥11.1 mmol\u002FL) or diabetic nephropathy.\n  3. Symptomatic deep vein thrombosis or pulmonary embolism within the past 6 months.\n  4. Active peptic ulcer or gastrointestinal bleeding within the past 6 months.\n  5. Severe congenital or acquired immunodeficiency.\n  6. Severe CNS diseases (e.g., catastrophic APS, uncontrolled epilepsy).\n  7. End-stage organ failure not attributable to PMN.\n* History of malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or thyroid cancer.\n* Specific treatment history or plans, including:\n\n  1. Prior receipt of any cell therapy (e.g., MSCs, HSCT).\n  2. Major surgery within 24 weeks before or planned within 24 weeks after enrollment.\n  3. Planned kidney transplantation within 3 years.\n  4. History of substance abuse.\n* Participation in another interventional clinical trial within 3 months prior to enrollment.\n* Pregnant or lactating women.\n* Inability to understand the study or provide informed consent (e.g., severe dementia, mental illness).\n* Any other condition deemed by the investigator to increase risk, interfere with assessment, or affect compliance.",{"count":5,"type":20},[23],"This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.\n\nPrior to receiving CAR-T cell therapy, patients will undergo lymphodepletion chemotherapy with cyclophosphamide (fludarabine will be added if necessary). After prophylactic administration of antihistamines and acetaminophen, patients will be infused with CD19 CAR-T cells at a dose of 1×10⁶ cells\u002Fkg.\n\nIn the subsequent 2 weeks, patients will be hospitalized for monitoring of vital signs and adverse reactions. The planned follow-up duration of this study is 1 years.",[82],"Refractory Membranous Nephropathy","RECRUITING","2025-12-18",{"date":86,"type":38},"2025-12-24",{"date":88,"type":38},"2025-12-08",{"date":90,"type":20},"2028-07-31",{"name":44,"class":45},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100611469","phase-1-mesenchymal-stem-cells-for-chronic-kidney-diseases-100611469","NCT07240987","Mesenchymal Stem Cells for Chronic Kidney Diseases","A Randomized Controlled Study of Mesenchymal Stem Cells in the Treatment of Chronic Kidney Diseases","Inclusion Criteria:\n\n* Agreement to participate in the trial and provision of signed written informed consent\n* Pathological diagnosis of diabetic nephropathy or hypertensive renal damage\n* 15 ≤ eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m², UACR \\> 300 mg\u002Fg\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Extremely severe anemia (hemoglobin \\\u003C 30 g\u002FL)\n* Received blood product transfusion therapy within 1 month\n* Autosomal dominant or recessive polycystic kidney disease (ADPKD)\n* History of kidney transplant or other solid organ transplant\n* Active systemic or localized infection (e.g., pneumonia, osteomyelitis)\n* Allergy to stem cells themselves or stem cell-related culture medium\n* History of allergic reaction to cell products (e.g., blood transfusion, platelets)\n* History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis)\n* History of malignancy or current malignant disease\n* Elevated tumor markers (AFP, CEA, CA199, CA125, etc.)\n* Pregnant women or women with plans for pregnancy within 3 months after MSC therapy\n* Participation in drug-related clinical trials within the past 2 months\n* Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health",{"count":100,"type":20},32,[23,24],"This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.",[104,105,106],"Kidney Disease, Chronic","Diabetic Kidney Disease (DKD)","Hypertensive Nephropathy",{"date":86,"type":38},{"date":109,"type":20},"2026-01-01",{"date":111,"type":20},"2027-08-31",{"name":44,"class":45},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":46},"100608215","early-phase-1-a-single-arm-investigator-initiated-tria-iit-evaluating-the-safety-and-preliminary-efficacy-of-autologous-drug-loaded-neutrophils-neumed-in-patients-with-unresectable-pancreatic-cancer-100608215","NCT07198659","A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer","A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer（NeuMed-uPC）","NeuMed-uPC","Inclusion Criteria:\n\n* 18-70 years\n* Obtain an informed consent form voluntarily signed by the patient themselves\n* patients with Unresectable Pancreatic Cancer confirmed by Histopathology\n* Patients who either: 1) have received standard first-line treatments, proven ineffective or causing intolerable adverse effects; or 2) have not received the standard first-line treatments and voluntarily opt for Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy\n* EOCG score ≤ 2 and expected survival time ≥ 3 months\n* Liver, kidney and bone marrow functions are basically normal\n\nExclusion Criteria:\n\n* Patients who required anti coagulant therapy\n* Patients with active infectious diseases or a history of bone marrow or organ transplantation\n* Patients with autoimmune diseases or autoinflammatory diseases\n* Patients with a history of severe cardiovascular or cerebrovascular diseases or interstitial lung disease or non-infectious pneumonia\n* Patients who have received live vaccines within 30 days prior to enrollment\n* Patients with no response to bone marrow mobilization\n* Other patients deemed unsuitable for enrollment by the investigator","70 Years",{"count":123,"type":20},3,[125],"EARLY_PHASE1","The goal of this clinical trial is to learn if Autologous Drug-Loaded Neutrophils (NeuMed) can treat patients with Unresectable Pancreatic Cancer. The drug carried by the Autologous Neutrophils is Monomethyl Auristatin E. The main questions it aims to answer are: First, to verify the safety of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer. Second, to assess the anti-tumor efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer.",[128],"Unresectable Pancreatic Cancer",[130,128,131],"Autologous Drug-Loaded Neutrophils (NeuMed)","Monomethyl Auristatin E (MMAE)","2025-09-26",{"date":134,"type":38},"2025-09-30",{"date":136,"type":38},"2025-07-14",{"date":138,"type":20},"2027-07-14",{"name":44,"class":45},""]